Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Saved in:
Bibliographic Details
Title: Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
Authors: Motzer, R.J.1 (AUTHOR) motzerr@mkscc.org, Albiges, L.2 (AUTHOR), Treviño Aguirre, S.A.3 (AUTHOR), Kanesvaran, R.4 (AUTHOR), Centkowski, P.5 (AUTHOR), Reimers, M.A.6 (AUTHOR), Sade, J.P.7 (AUTHOR), Pouessel, D.8 (AUTHOR), Biscaldi, E.9 (AUTHOR), Esteban, E.10 (AUTHOR), Arranz Arija, J.Á.11 (AUTHOR), Tykodi, S.S.12 (AUTHOR), van Kooten Losio, M.13 (AUTHOR), Dighe, A.14 (AUTHOR), Ma, H.15 (AUTHOR), Valmeekam, V.15 (AUTHOR), Simmons, A.15 (AUTHOR), Scheffold, C.15 (AUTHOR), Andrianova, S.15 (AUTHOR), Braun, D.A.14 (AUTHOR)
Source: Annals of Oncology. Jun2026, Vol. 37 Issue 6, p861-871. 11p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2026.02.011